The last time I wrote about Centessa Pharmaceuticals plc (NASDAQ:CNTA), it was in a Seeking Alpha article entitled “Centessa: Hemophilia B Data Readout In 2024 is Major Turning Point.” One of the ...

As traders and investors turn their focus to 2025, one area poised to attract significant attention is the dividend sector, as market participants consistently seek reliable sources of income. As a ...

Shares MSCI Chile ETF offers diversified exposure across various sectors. Click here to find out why I think Chilean equities are a buying opportunity in 2025.

I initially rated BUCK as Sell due to volatility and unpredictability, but new information regarding BUCK's operational ...

GATX's financial performance has been good but debt increased by 88% over six years. See why I think Treasuries offer ...

Alibaba’s stock lost most of its momentum after the Chinese stimulus package failed to impress the market. Find out why we ...

Renesas shares appear undervalued by over 30%, presenting a contrarian investment opportunity for patient investors. Find out ...

TSMC’s future looks more uncertain than ever, with the rise of geopolitical risks. Click here to find out why we rate TSM ...

Shell plc, known as Royal Dutch Shell, boasts a market cap of almost $200 billion, making it a significant player in the ...

Praxis Precision Medicines, Inc., a promising clinical stage biopharma concern, has seen significant stock gains in the ...

Artivion was known as CryoLife, Inc. until early 2022 when it took its current name. The company is headquartered in Kennesaw, GA. After the rise in the shares since the last time we looked at this ...

I maintain a buy rating on VB due to its reasonable valuation, solid earnings growth, and bullish chart, despite a recent 10% ...